Clinical stage biotechnology company Evommune Inc announced on Monday that the first patient has been enrolled in a Phase 2 trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD).
EVO301 is a serum albumin Fab-associated IL-18BP fusion protein designed to neutralise upregulated IL-18 activity, which is implicated in a range of inflammatory and autoimmune diseases.
The multi-centre, randomised, double-blind, placebo-controlled, proof-of-concept trial will evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. The primary objective is to characterise the efficacy of EVO301, assessed by the percentage change in EASI from baseline at week 12. EASI, the Eczema Area and Severity Index score, is a tool used to measure the extent and severity of atopic dermatitis.
J Mark Jackson, MD, Evommune vice president, Clinical Development, said: "AD is a highly heterogenous disease, and for this reason, there remains a need for more effective treatments. While currently available therapies may improve some signs and symptoms, many AD patients do not respond optimally, and we believe EVO301 could, if approved, fulfil their search for a new and better treatment option. Based on our robust preclinical and Phase 1 clinical data, we are eager to confirm that the extended half-life expected with this IL-18BP fusion protein, has the potential to better serve patients with moderate-to-severe AD."
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025